Visudyne (correction)
Executive Summary
"The Pink Sheet" incorrectly identified the approval date for Novartis/QLT's Visudyne photodynamic therapy in a recent story (1"The Pink Sheet" July 25, 2005, p. 16). The therapy was approved in April 2000...
You may also be interested in...
Genentech Could Initiate Lucentis Rolling BLA Filing As Early As December
Genentech could begin a rolling BLA filing for its neovascular (wet) age-related macular degeneration therapy Lucentis (ranibizumab) as early as December if the company is granted fast-track designation by FDA
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.